Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, USA.
Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, USA; School of Applied Engineering and Technology, New Jersey Institute of Technology, Newark, NJ, USA.
Vision Res. 2021 Aug;185:58-67. doi: 10.1016/j.visres.2021.03.014. Epub 2021 Apr 23.
This study sought to test the hypothesis that significant differences would be observed in clinical measures, symptoms, and objective assessments of vergence eye movements between children with typically developing convergence insufficiency (TYP-CI) and children with persistent post-concussion symptoms with convergence insufficiency (PPCS-CI). Data from age-matched binocularly normal controls (BNC) were used for comparison. Data from three groups of children 11 to 17 years of age are presented: BNC (N = 11), TYP-CI (N = 10), and PPCS-CI (N = 15). Clinical measures of vergence, accommodation, and symptom severity were collected. Symmetrical 4° disparity vergence eye movements were quantified with an eye tracker integrated into a head-mounted display (Oculus DK2). Peak velocity and final response amplitude of convergence and divergence eye movement responses were assessed. The mean near point of convergence (break) was more receded (worse), the amplitude of accommodation more deficient, and convergent and divergent peak velocities slower in the PPCS-CI group compared with the TYP-CI and BNC groups. These results suggest that PPCS-CI may be a different clinical entity than TYP-CI. Hence, more research is warranted to determine whether the therapeutic interventions that are effective for TYP-CI can also be used for PPCS-CI populations.
本研究旨在验证以下假设,即患有典型集合不足(TYP-CI)和患有持续性脑震荡后集合不足(PPCS-CI)的儿童在临床测量、症状和聚散眼动的客观评估方面会出现显著差异。使用年龄匹配的双眼正常对照组(BNC)的数据进行比较。研究对象为三组 11 至 17 岁的儿童:BNC(N=11)、TYP-CI(N=10)和 PPCS-CI(N=15)。收集了聚散的临床测量、调节和症状严重程度的数据。使用集成在头戴式显示器中的眼动追踪器(Oculus DK2)量化了对称 4°视差聚散眼动。评估了集合和发散眼动反应的峰值速度和最终反应幅度。与 TYP-CI 和 BNC 组相比,PPCS-CI 组的集合近点(断点)更靠后(更差),调节幅度更不足,集合和发散的峰值速度更慢。这些结果表明,PPCS-CI 可能与 TYP-CI 是不同的临床实体。因此,需要进行更多的研究,以确定对 TYP-CI 有效的治疗干预措施是否也可用于 PPCS-CI 人群。